Korea Gongjin-Dan
Commercial- Indications
- Male potency, Mental exhaustion, Physical exhaustion, Circulatory disorders, Emotional disorders, Chronic fatigue, Palpitation, Insomnia
Company intelligence / Profile preview
Songjeongo OM Clinic appears to be a healthcare clinic and small-scale OTC drug labeler/manufacturer rather than a biotechnology or pharmaceutical development company. Publicly available U.S. drug-label sources identify the clinic as the labeler and manufacturer of Korea Gongjin-Dan, an orally administered pellet product containing panax ginseng fruit and marketed in the U.S. as a human OTC drug product. The available evidence suggests the organization is associated with traditional Korean medicine and wellness-oriented products, not a conventional drug-development pipeline. No evidence was found of clinical-stage R&D programs, platform technology, major pharma partnerships, or institutional financing typical of biotech companies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Songjeongo OM Clinic.